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. A second miRNA gene, let-7, was found in 2000, in worms [4, 5] . miRNAs have now emerged as widely acting regulatory molecules that silence their cognate target genes, either by degrading mRNA molecules or, more frequently in mammalian cells, by inhibiting their translation [6] . Computational and biological evidence suggests that miRNA-mediated gene regulation represents a fundamental mechanism of post-transcriptional regulation with diverse functional effects [7] .
miRNAs have been implicated in a range of biological processes including cancer [8, 9] , development of the limb [10, 11] , lung [12] , and haematopoetic system [13] . In addition, a number of miRNAs have been characterized as modulators of myogenic differentiation [14] and there is increasing evidence for miRNA involvement in myopathies and muscular dystrophies [15] [16] [17] [18, 19] . Combined computational-experimental analyses suggest that at least ~30% of human mRNAs are miRNA targets [20] . Once 
Muscle-specific miRNAs
The functional characterization of miR-1 and miR-133 has been an important step in our understanding of miRNA-mediated muscle development (summarized in Fig. 1 [24] . miR-1 and miR-133 are transcribed in a muscle-specific manner during development from a common polycistronic gene [25] and modulate muscle growth and differentiation by regulating SRF and MEF2 activity, thereby establishing negative feedbacks loops within muscle cell lineages [25] . Recent 
Additionally, these transcription factors use upstream and intragenic enhancers to activate transcription of bicistronic miR-1/133 clusters encoding miR-1 and miR-133 in differentiated skeletal muscle. miR-1 represses expression of HDAC4 (histone deacetylase 4), a signal-dependent repressor of MEF2 activity, thereby establishing a negative feedback loop to modulate miR-1 and miR-133 expression and promoting myoblast differentiation. As myogenesis progresses from the myoblast stage to the myotube stage, the level of the muscle-specific miR-133 increases and miR-133 represses expression of serum response factor (SRF), a positive regulator of miR-1/133 expression and repressor of myoblast proliferation. Upon differentiation, miR-181 is also up-regulated, resulting in down-regulation of Hox-A11 and in the release of MYOD1 expression. As a result, myogenin (MYOG) and muscle marker proteins including MHC (myosin heavy chain) are up-regulated. In parallel, activation of MYOD1 increases the expression of the primary miR-206 transcript which in turn lead to down-regulation of Follistatin-like 1 (FSTL1) and to the repression of Utrophin (Utrn) expression and through a mechanism that is not yet known promotes muscle differentiation.
Consistent with these findings, similar to miR-1, another miRNA, miR-206, has also been characterized as a muscle regulator in recent studies and has also been shown to promote myoblast differentiation [27] [28] [29] . Gap [34] . This results in a phenotype that matches Myostatin loss of function mutations in mice, cattle and humans [35] . [38] .
Non-muscle-specific miRNAs
Another example for a non-muscle-specific miRNA involved in myogenesis is miR-24. Members of TGF-␤ have been shown to potently inhibit terminal differentiation of cultured myoblasts by down-regulating MRFs [39, 40] . Myostatin, a member of the TGF-␤ family, has been shown to be a negative regulator of muscle differentiation and growth [41, 42] . Recent studies revealed that SMAD3 mediates the suppression of myogenesis by TGF-␤ through suppressing the expression of E-box muscle genes and MEF2 proteins [43, 44] , whereas SMAD7 has been implicated in promoting and enhancing myogenesis by interacting with MYOD1 and abrogating of Myostatin signalling [45] .
Recently, miR-24 was shown as an essential miRNA for the modulation of TGF-␤-inhibited myogenesis [46] [53] . Interestingly, the rs11614913 SNP in miRNA-196a was recently reported as an indicator of non-small cell lung cancer (NSCLC) [54] . Individuals who were homozygous for the CC mutation had statistically significantly higher mortality compared with individuals whom had either TT or CT at the locus. [55] . [17] . [17, 56] [17] . Similarly, nearly all of the LGMD myopathies have a significant up-regulation of miRNAs-100, -103, -107; whereas DMD patients do not [17] . As the cost of arrays subsequently decreases as the technology becomes more mainstream and high-throughput, the usage of miRNAs as biomarkers in diagnostic laboratories should vastly increase.
The usage of miRNAs in the detection of various cancers is one of the most promising areas of biomarker identification (reviewed in [52]). Cancer in general terms remains problematic in its diagnoses that rely primarily on the detection of overexpressed levels of various antigens such as prostate-screening antigen (PSA) for prostate cancer detection. Often cancers are not detected until they have metastasized and few treatment options for the patient remain. Several recent studies have highlighted the usage of specific miRNAs in various arrays of large-scale cancer studies. A recent study by Szafranska and colleagues identified miR-217 as significantly down-regulated and miR-196a significantly overexpressed in patients with the difficult to diagnose pancreatic ductal adenocarcinoma (PDAC)

It is hypothesized that cancer in general may have a set of miRNAs that are dysregulated during uncontrolled cell proliferation. The miRNA polycistron miR-17-92 locus has been characterized as an oncogene and is highly overexpressed in B-cell lymphoma
Indeed, the miR-17-92 locus is activated upon the overexpression of c-myc a hallmark of B-cell lymphomas diagnoses. Thus, it is
More difficult to diagnosis myopathies such as nemaline myopathy (NM), which can be detected by mutations in six filamental genes, can be distinguished from the inflammatory myopathies such as inclusion body myositis (IBM) or dermatomyositis (DM) based on the expression levels of specific inflammatory miRNAs-155 and miR146b among others
. A positive Facioscapulohumeral muscular dystrophy (FSHD) diagnosis could be distinguished from DMD based on the lack of dysregualtion of miRNAs-381 and -382 found in FSHD patients
miRNA therapeutic promise Locked nucleic acids (LNAs) and antagomiRs
The ability to inhibit miRNA function through the use of complimentary sequences makes miRNAs an attractive candidate for therapeutic treatments. As noted, several miRNAs are significantly up-regulated in muscular dystrophies and other myopathies [17] . The ability to inhibit these up-regulated miRNAs using locked nucleic acids (LNAs) [30] . Overexpression of miRNA in mouse myoblasts resulted in increased differentiation, regardless of the levels of serum in the media [28] .
Likewise, inhibition of miR-206 by antagomirs resulted in the inhibition of myogenic differentiation. These findings would suggest that the overexpression of miR-206 observed in the diaphragm muscle of mdx mice might also explain the accelerated differentiation and cell cycle kinetics in the muscle satellite cells isolated from the diaphragm muscle of mdx mice [61]. Delivery of LNAs targeting miR-206 to the diaphragm muscles of patients might reverse the accelerated differentiation observed in DMD patients and increase life-span. Given the restrictive expression of miR-206 to skeletal muscle, intravenous or direct intra-muscular injection of LNAs targeting miR-206 would most likely have relatively minor side effects.
Overexpression of miRNAs in myopathies
A modest cluster of miRNAs, both skeletal muscle-specific and non-skeletal muscle-specific, are significantly down-regulated in various myopathies of patients [17] . In both cardiac and skeletal muscle hypertrophy, the cardiac/skeletal muscle-enriched miRNA, miR-133a, was strongly down-regulated [16, 62] . Thus, the option of correcting the lower levels of specific miRNAs becomes another tool for treatment of myopathies. [63, 64] . Intramuscular injections of either the 21-24 nucleotide miRNA or stem-loop structure overexpression virus would ensure successful delivery of the miRNA to the affected muscle. [65] . Many of the miRNAs that were dysregulated in different myopathies have essential functions in both myogenesis and the inflammatory response [17] . miRNA-181a/b is an upstream repressor of Hox-A11 transcription, a validated repressor of MYOD1 levels and is significantly up-regulated during skeletal muscle regeneration [36] . However, miR-181a/b also plays an essential role in the maturation of T cells and their affinity for antigen recognition [66] . Additional miRNAs, such as miR-1, whereas substantially expressed in skeletal muscle, have broad functions as regulators of stem cell differentiation, cell cycle progression, and cardiac conduction [67, 68] . The ability to achieve specificity and selectivity in targeting miRNAs of a specific cell type is a significant barrier that must be explored if non-skeletal muscle-specific miRNAs are to be used as a treatment for myopathies. 
Overexpression of miRNAs in vivo would most likely involve injection of a stable oligonucleotide that would be cleaved to a 21-24 nucleotide strand by endogenous mechanisms or the injection of an miRNA overexpression virus. Recent advances in the viral infection levels and decreased toxicity using adeno-associated viruses (AAV) have made this system an attractive delivery method for gene therapy
Specificity of miRNA treatment
miRNAs as regulators of myogenic stem cells
